BR112015005882A2 - formulações farmacêuticas em suspensão compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão - Google Patents

formulações farmacêuticas em suspensão compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão

Info

Publication number
BR112015005882A2
BR112015005882A2 BR112015005882A BR112015005882A BR112015005882A2 BR 112015005882 A2 BR112015005882 A2 BR 112015005882A2 BR 112015005882 A BR112015005882 A BR 112015005882A BR 112015005882 A BR112015005882 A BR 112015005882A BR 112015005882 A2 BR112015005882 A2 BR 112015005882A2
Authority
BR
Brazil
Prior art keywords
propionic acid
low melting
acid derived
melting point
derived particles
Prior art date
Application number
BR112015005882A
Other languages
English (en)
Inventor
K Vuppala Murali
Bagchi Saumitra
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BR112015005882A2 publication Critical patent/BR112015005882A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "formulações farmacêuticas em suspensão compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão". são reveladas partículas derivadas do ácido propiônico com baixo ponto de fusão que são fluidas e apresentam ardência na garganta significativamente reduzida ou eliminada. também são revelados um método de fabricação das partículas derivadas do ácido propiônico com baixo ponto de fusão; das formas de dosagem contendo as partículas derivadas do ácido propiônico com baixo ponto de fusão; métodos de fabricação das formas de dosagem; e métodos de tratamento usando as formas de dosagem.
BR112015005882A 2012-09-18 2013-09-16 formulações farmacêuticas em suspensão compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão BR112015005882A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702442P 2012-09-18 2012-09-18
PCT/US2013/059942 WO2014047007A1 (en) 2012-09-18 2013-09-16 Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles

Publications (1)

Publication Number Publication Date
BR112015005882A2 true BR112015005882A2 (pt) 2017-07-04

Family

ID=49231646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005882A BR112015005882A2 (pt) 2012-09-18 2013-09-16 formulações farmacêuticas em suspensão compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão

Country Status (9)

Country Link
US (2) US20140080912A1 (pt)
EP (1) EP2897647A1 (pt)
CN (1) CN104640570B (pt)
AU (1) AU2013318362A1 (pt)
BR (1) BR112015005882A2 (pt)
CA (1) CA2884440A1 (pt)
RU (1) RU2015114437A (pt)
WO (1) WO2014047007A1 (pt)
ZA (1) ZA201502613B (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
WO1999013864A2 (en) * 1997-09-19 1999-03-25 Shire Laboratories, Inc. Solid solution beadlet
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
CN1655762B (zh) * 2002-06-17 2010-05-26 塔罗制药美国公司 布洛芬混悬剂
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
FR2853528B1 (fr) * 2003-04-11 2008-08-29 Oreal Composition cosmetique comprenant un polymere filmogene amorphe et presentant un profil thermique particulier
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets

Also Published As

Publication number Publication date
ZA201502613B (en) 2017-11-29
CN104640570B (zh) 2017-04-26
US20160051678A1 (en) 2016-02-25
CA2884440A1 (en) 2014-03-27
US20140080912A1 (en) 2014-03-20
RU2015114437A (ru) 2016-11-10
WO2014047007A1 (en) 2014-03-27
EP2897647A1 (en) 2015-07-29
AU2013318362A1 (en) 2015-03-26
CN104640570A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
BR112012032028A2 (pt) compostos de tioacetato, composições e métodos de uso.
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015029970A2 (pt) inibidores de cinase
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BR112014026703A2 (pt) inibidores de dna-pk
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
SG10201811186XA (en) Purification of proteins
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.